Vicentra Closes Eur 65M (Usd 74M) Series C Funding To Expand Footprint Of World'S Smallest Insulin Pump Across Europe
Vicentra Closes Eur 65M (Usd 74M) Series C Funding To Expand Footprint Of World'S Smallest Insulin Pump Across Europe
12/16/21, 3:00 AM
Location
utrechtMoney raised
€65 million
Round Type
series c
ViCentra, the company behind Kaleido, the world's smallest and lightest wearable insulin pump ("patch pump"), announces the closing of a EUR 65 million (USD 74 million) Series C financing. The investment round was led by new investor Partners in Equity BV, the Amsterdam based Venture Capital firm with a long-term focus. Existing investors LSP, INKEF Capital and Health Innovations also participated in the investment.
Company Info
Location
utrecht, utrecht, netherlands
Additional Info
ViCentra B.V., with headquarters in Utrecht, the Netherlands develops, manufactures and markets next generation insulin pumps and other products to treat people with diabetes. The company's flagship product is the Kaleido insulin pump which is CE marked and commercially released in certain European countries. ViCentra was founded in 2013 and is backed by Health Innovations, INKEF Capital, LSP, Invest-NL, Partners in Equity BV and Kreos Capital. The highly experienced team has expertise in scaling manufacturing, commercialisation and regulatory filing. More information about ViCentra can be found at www.hellokaleido.com.